Developmental defects and childhood cancer

Current Opinion in Pediatrics

Volumn 21, Issue 6, 2009, Pages 717-723

  Slavin, Thomas P ^a,b,c   Wiesner, Georgia L ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Beckwith Wiedemann syndrome; Cancer genetics; Childhood cancer syndromes; Cowden syndrome; Hemihypertrophy; Neurofibromatosis type 1; PTEN hamartoma tumor syndrome

Indexed keywords

APC PROTEIN; ATM PROTEIN; BLOOM SYNDROME HELICASE; FANCONI ANEMIA GROUP A PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR PAX6; VON HIPPEL LINDAU PROTEIN; WT1 PROTEIN;

ADENOMATOUS POLYP; ATAXIA TELANGIECTASIA; BASAL CELL NEVUS SYNDROME; BECKWITH WIEDEMANN SYNDROME; BLOOM SYNDROME; BODY DYSMORPHIC DISORDER; BODY GROWTH; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD CANCER; COWDEN SYNDROME; DENYS DRASH SYNDROME; DEVELOPMENTAL DISORDER; DOWN SYNDROME; EARLY DIAGNOSIS; FAMILIAL CANCER; FANCONI ANEMIA; GENE MUTATION; GENETIC SCREENING; GROWTH DISORDER; HAMARTOMA; HEMIHYPERTROPHY; HUMAN; KLINEFELTER SYNDROME; MEDICAL SPECIALIST; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; ONCOGENE RAS; PATIENT REFERRAL; PEUTZ JEGHERS SYNDROME; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; SKIN DISEASE; SOTOS SYNDROME; THUMB MALFORMATION; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE; WAGR SYNDROME;

ADOLESCENT; BECKWITH-WIEDEMANN SYNDROME; CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEOPLASMS; NEUROFIBROMATOSIS 1;

EID: 74549154987     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328332c612     Document Type: Review

References (37)

1. Ries LAG, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review 1973-1995, National Cancer Institute, 1998. http://www.seer.ims.nci.nih. gov.
2. Grovas A, Fremgen A, Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997; 80:2321-2332.
3. Chompret A, Brugiè res L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82:1932-1937.
4. Lohmann DR, Gallie BL. Retinoblastoma. NCBI GeneTest, 7 May 2007. www.geneclinics.org. [Accessed June 2009]
5. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1:157-162.
6. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123:124-133.
7. Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol 2006; 13:21-26.
8. Jorge AA, Malaquias AC, Arnhold IJ, et al. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/ MAPK pathway. Horm Res 2009; 71:185-193.
9. National Institutes of Health Consensus Development Conference statement: neurofibromatosis. Arch Neurol Chicago 1988; 45:575-578.
10. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 (NF1). J Med Genet 2007; 44:81-88.
11. National Comprehensive Cancer Network. NCCN practice guidelines: genetics/familial high risk cancer. Oncology 1999; 13:161-186.
12. Lips CJ, Hoppener JW, Van Nesselrooij BP, Van der Luijt RB. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. J Intern Med 2005; 257:69-77.
13. Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005; 257:60-68.
14. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005; 19:5-12.
15. Schimke RN, Collins DL, Dtolle CA. Von Hippel Lindau Syndrome. NCBI GeneTest, 20 March 2007. www.geneclinics.org. [Accessed June 2009].
16. Clericuzio CL. Recognition and management of childhood cancer syndromes: a systems approach. Am J Med Genet 1999; 89:81-90.
17. Lindor NM, McMaster ML, Lindor CJ, et al. Concise handbook of familial cancer susceptibility syndromes: second edition. J Natl Cancer Inst Monogr 2008; 38:1-93.
18. Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genet Med 2009; 11:220-222.
19. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24:2570-2575.
20. Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006; 95:233-238. (Pubitemid 44050923)
21. Sharif S, Moran A, Huson SM, et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007; 44:481-484.
22. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2005; 137C:12-23.
23. Hatada I, Nabetani A, Morisaki H, et al. New p57KIP2 mutations in Beckwith- Wiedemann syndrome. Hum Genet 1997; 100:681-683.
24. Thorburn MJ, Wright ES, Miller CG, Smith-Read EH. Exomphalos- macroglossia- gigantism syndrome in Jamaican infants. Am J Dis Child 1970; 119:316-321.
25. Martinez R, Martinez Y. Clinical features in the Wiedemann-Beckwith syndrome. Clin Genet 1996; 50:272-274.
26. Eng C. PTEN Hamartoma tumor syndrome (PHTS). NCBI GeneTest, 5 May 2009. www.geneclinics.org. [Accessed June 2009]
27. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22:183-198.
28. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 2005; 65:8096-8100.
29. Sarquis MS, Agrawal S, Shen L, et al. Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan- Riley-Ruvalcaba Syndrome. Am J Human Genet 2006; 79:23-30. (Pubitemid 43927373)
30. Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999; 7:267-273.
31. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37:828-830.
32. Gorlin RJ, Cohen MM, Condon LM, et al. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992; 44:307-314.
33. Biesecker LG, Happle R, Mulliken JB, et al. Proteus syndrome: diagnostic criteria, differential diagnosis, and patient evaluation. Am J Med Genet 1999; 84:389-395.
34. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29:222-233.
35. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007; 7:35-45.
36. Borthakur G, Cortes JE. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 2004; 79:411-419.
37. Wojtkowiak JW, Fouad F, LaLonde DT, et al. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther 2008; 326:1-11.